D
Desamparados Roda
Researcher at The Royal Marsden NHS Foundation Trust
Publications - 19
Citations - 1902
Desamparados Roda is an academic researcher from The Royal Marsden NHS Foundation Trust. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 7, co-authored 12 publications receiving 1510 citations. Previous affiliations of Desamparados Roda include Institute of Cancer Research.
Papers
More filters
Journal ArticleDOI
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo,Suzanne Carreira,Shahneen Sandhu,Susana Miranda,Helen Mossop,Raquel Perez-Lopez,Daniel Nava Rodrigues,Dan R. Robinson,Aurelius Omlin,Nina Tunariu,Gunther Boysen,Nuria Porta,Penny Flohr,Alexa Gillman,Ines Figueiredo,Claire Paulding,George Seed,Suneil Jain,Christy Ralph,Andrew Protheroe,Syed A. Hussain,Robert Jones,Tony Elliott,Ursula McGovern,Diletta Bianchini,Jane C. Goodall,Zafeiris Zafeiriou,Chris T. Williamson,Roberta Ferraldeschi,Ruth Riisnaes,Bernardette Ebbs,Gemma Fowler,Desamparados Roda,Wei Yuan,Yi-Mi Wu,Xuhong Cao,Rachel Brough,Helen Pemberton,Roger A'Hern,Amanda Swain,Lakshmi P. Kunju,Rosalind A. Eeles,Gerhardt Attard,Christopher J. Lord,Alan Ashworth,Mark A. Rubin,Karen E. Knudsen,Felix Y. Feng,Arul M. Chinnaiyan,Emma Hall,Johann S. de Bono +50 more
TL;DR: Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate.
Journal ArticleDOI
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers
Timothy A. Yap,Timothy A. Yap,Rebecca Kristeleit,Vasiliki Michalarea,Stephen J. Pettitt,Joline S.J. Lim,Suzanne Carreira,Desamparados Roda,Desamparados Roda,Rowan Miller,Ruth Riisnaes,Susana Miranda,Ines Figueiredo,Daniel Nava Rodrigues,Sarah Emily Ward,Sarah Emily Ward,Ruth Matthews,Ruth Matthews,Mona Parmar,Mona Parmar,Alison Turner,Alison Turner,Nina Tunariu,Neha Chopra,Neha Chopra,Heidrun Gevensleben,Nicholas C. Turner,Nicholas C. Turner,Ruth Ruddle,Florence I. Raynaud,Shaun Decordova,Karen E Swales,Laura Finneran,Emma Hall,Paul Rugman,Justin P.O. Lindemann,Andrew Foxley,Christopher J. Lord,Udai Banerji,Udai Banerji,Ruth Plummer,Bristi Basu,Juanita Lopez,Juanita Lopez,Yvette Drew,Johann S. de Bono,Johann S. de Bono +46 more
TL;DR: An investigator-initiated phase I trial utilizing a prospective intrapatient dose-escalation design to assess two schedules of capivasertib (AKT inhibitor) with olaparib (PARP inhibitor) in 64 patients with advanced solid tumors found the combination was well-tolerated.
Journal ArticleDOI
Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials.
Elena Geuna,Desamparados Roda,Saeed Rafii,Begona Jimenez,Marta Capelan,Karim Rihawi,Filippo Montemurro,T. A. Yap,Stan B. Kaye,J.S. de Bono,L. R. Molife,Udai Banerji +11 more
TL;DR: PI3K–AKT–mTOR inhibitors are associated with small but statistically significant increased risk of high-grade hyperglycaemia compared with non-PAM targeting agents, however, PAMi-induced hyper glycaemia was not found to be associated with severe metabolic complications in this non-diabetic population of patients with advanced cancers.
Journal ArticleDOI
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study
Christina Guo,Maxime Chénard-Poirier,Desamparados Roda,Maria de Miguel,Samuel John Harris,Irene Moreno Candilejo,Priya Sriskandarajah,Wen Xu,Mariana Scaranti,Anastasia Constantinidou,Jenny King,Mona Parmar,Alison Turner,Suzanne Carreira,Ruth Riisnaes,Laura Finneran,Emma Hall,Yuji Ishikawa,Kiyohiko Nakai,Nina Tunariu,Bristi Basu,Martin Kaiser,Juanita Lopez,Anna Minchom,Johann S. de Bono,Udai Banerji +25 more
TL;DR: This trial aimed to investigate the safety and toxicity profile of intermittent dosing schedules of CH5126766, and the antitumour activity of this drug in patients with solid tumours and multiple myeloma harbouring RAS-RAF-MEK pathway mutations.
Journal ArticleDOI
Higher risk of infections with PI3K-AKT-mTOR pathway inhibitors in patients with advanced solid tumors on phase I clinical trials
Saeed Rafii,Desamparados Roda,Elena Geuna,Begona Jimenez,Karim Rihawi,Marta Capelan,Timothy A. Yap,L Rhoda Molife,Stanley B. Kaye,Johann S. de Bono,Udai Banerji +10 more
TL;DR: Inhibitors of the PI3K–AKT–mTOR pathway can be associated with a higher risk of infection when combined with chemotherapy or myelosuppressive agents.